Cargando…
Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases
BACKGROUND: High-dose intravenous immune globulins (IVIg) are frequently used in refractory juvenile dermatomyositis (JDM) but are often poorly tolerated. High-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins (fSCIg) allow the administration of much higher doses of immu...
Autores principales: | Speth, Fabian, Haas, Johannes-Peter, Hinze, Claas H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5022227/ https://www.ncbi.nlm.nih.gov/pubmed/27623619 http://dx.doi.org/10.1186/s12969-016-0112-6 |
Ejemplares similares
-
Human immune globulin 10% with recombinant human hyaluronidase in multifocal motor neuropathy
por: Herraets, Ingrid J. T., et al.
Publicado: (2019) -
Intravenous Immune Globulin in Amyopathic Dermatomyositis - Report of Two Cases and Review of the Literature
por: Cafardi, John M., et al.
Publicado: (2015) -
Current management of juvenile dermatomyositis in Germany and Austria: an online survey of pediatric rheumatologists and pediatric neurologists
por: Hinze, Claas H., et al.
Publicado: (2018) -
Intravenous immune globulin suppresses angiogenesis in mice and humans
por: Yasuma, Reo, et al.
Publicado: (2016) -
Recurrent Myocarditis Treated with Intravenous Immune Globulin and Steroids
por: Schwartz, Brandon H., et al.
Publicado: (2022)